Paving the Way to Better Choices for Veterans With Lung Cancer: A Shared Decision-Making Approach to Treatment
This activity contains:
- CME/CPE/CNE-Certified Live Grand Rounds and Webinars
- Downloadable Slide Deck with Facilitator’s Guide
(a non-certified educational resource)
The goal of this activity is to provide strategies for physicians to incorporate a shared decision making approach into the optimal care of veterans with lung cancer.
Approximately 35,000 new cases of cancer occur in military veterans each year; cancer is the second leading cause of death among military veterans. According to the late Rear Admiral Philip J. Coady, USN, former Chairman of the Board of Directors of the Lung Cancer Alliance, “lung cancer is an urgent priority among veterans. Not only is the incidence higher, but the survival is lower than in civilian populations.” In addition, treatment planning in lung cancer is complex and challenging due to significant comorbidities, demographic factors, and/or disease characteristics that must be addressed to optimize the care of military veterans. Clinicians within the Veterans Affairs (VA) system must work within the confines of the VA formulary restrictions, which can affect optimal treatment. The current knowledge of the epidemiology and special needs of this patient population may be inadequate among clinicians who work in VA facilities.
The rapidly evolving treatment landscape challenges clinicians to consistently reach evidence-aligned clinical conclusions and offer patients accurate information about outcomes. Healthcare providers increasingly need education support within a team-based approach to manage cognitive overload and more quickly convert new information into treatment recommendations for their patients. Military veterans require services and support to maintain their quality of life and daily activities, and the leaders of the Veterans Health Administration (VHA) are urging the adoption of shared decision making (SDM) for choices about long-term services and support for military veterans. The VHA reported that long-term services and supports do not have a “one-size-fits-all” answer for all, so it is critical to use SDM. The SDM model is intended to engage military veterans, their families or caregivers, and the full team that works in support of these military veterans, healthcare and long-term support service needs.
This activity will provide education for clinicians on the incidence and prevalence of lung cancer in military veterans as well as the demographic/risk factors associated with this patient population to make appropriate clinical and management decisions with the patient. Because clinicians who work in VA facilities may not realize the importance of patient engagement and SDM with veterans and their caregivers, education will also be provided to assist clinicians in engaging military veterans in treatment decisions using SDM approaches and prioritizing the timeliness of care, coordination of care, screening, and access to palliative care for military veterans.
- Activity Overview (5 min)
- Overview of lung cancer in VA Healthcare System (10 min)
- Overview of Treatment Beyond Chemotherapy (15 min)
- Integrating Shared Decision Making Into Care of Veterans (15 min)
- Clinical Case Challenges (15 min)
- Conclusion and Q&A
This activity is intended for Veterans Administration thoracic oncologists, medical oncologists, radiation oncologists, surgical oncologists, pulmonologists, pathologists, advanced practitioners, and pharmacists who treat and manage lung cancer.
At the conclusion of this activity, participants should be better able to:
- Discuss the incidence, prevalence, and demographic/risk factors associated with veterans with lung cancer
- Engage veteran patients in treatment decisions using shared decision-making approaches
- Prioritize the timeliness of care, coordination of care, screening, and access to palliative care for veterans
- Use molecular testing to support treatment recommendations for veterans who have non–small cell lung cancer
- Address emerging evidence on the efficacy of various targeted therapies in patients with NSCLC
Millie Das, MD
|D. Ross Camidge, MD, PhD|
Professor of Medicine/Oncology
Joyce Zeff Chair in Lung Cancer Research
University of Colorado Cancer Center
David H. Harpole, Jr., MD
Stephen V. Liu, MD
|Howard “Jack” L. West, MD|
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Pharmacists
This knowledge-based activity is approved for 1.0 contact hours of continuing pharmacy education credit. UAN 0592-0000-16-028-L01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.
Iowa Board of Nursing
AXIS is Iowa Board of Nursing Approved Provider Number 371, for 1.0 contact hour.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Millie Das, MD||Millie Das, MD reported nothing to disclose.|
|D. Ross Camidge, MD, PhD||Ross Camidge, MD, PhD reported a financial interest/relationship or affiliation in the form of: Consultant, G1 Therapeutics, AbbVie, Ariad Pharmaceuticals, Inc., Array BioPharma, Celgene Corporation., Clovis Oncology, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Orion|
David H. Harpole, Jr., MD
|David H. Harpole, Jr., MD reported nothing to disclose.|
|Stephen V. Liu, MD||Stephen V. Liu, MD, reported a financial interest/relationship or affiliation in the form of Consultant, Genentech, Inc., Ariad Pharmaceuticals, Inc., Boehringer Ingelheim; , Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Lilly, Pfizer, Inc., Pfizer, Inc., Taiho Pharmaceutical Co., Ltd., Threshold Phrmaceuticals, Genentech, Inc., Corvus|
|Howard “Jack” L. West, MD||Howard West , MD, reported a financial interest/relationship or affiliation in the form of: Consultant, Ariad Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Genentech/Roche, Guardant Health, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.; Speaker, Ariad Pharmaceuticals., Genentech/Roche.|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda Gracie-King, MS, Ronald Viggiani, MD, Jocelyn Timko, and Marilyn Haas, PhD, RN, CNS, ANP-BC state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
This activity is supported by educational grants from Genentech and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
There is no fee for this educational activity.
This activity is provided by:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Attendance